Judy C Boughey, Kari M Rosenkranz, Karla V Ballman, Linda McCall, Bruce G Haffty, Laurie W Cuttino, Charlotte D Kubicky, Huong T Le-Petross, Armando E Giuliano, Kimberly J Van Zee, Kelly K Hunt, Olwen M Hahn, Lisa A Carey, Ann H Partridge
PURPOSE: Breast-conserving therapy (BCT) is the preferred treatment for unifocal breast cancer (BC). The oncologic safety of BCT for multiple ipsilateral breast cancer (MIBC) has not been demonstrated in a prospective study. ACOSOG Z11102 (Alliance) is a phase II, single-arm, prospective trial designed to evaluate oncologic outcomes in patients undergoing BCT for MIBC. PATIENTS AND METHODS: Women age 40 years and older with two to three foci of biopsy-proven cN0-1 BC were eligible...
June 10, 2023: Journal of Clinical Oncology